Pharmaceutical Companies

Lilly disclosed the decision as part of its second-quarter results, removing a phase 1/2 study of LY3884961 in Gaucher disease type 1 (GD1) from its pipeline.

The new venture will initially manufacture biologic drug substances that the two companies mutually select for global markets.

AsymBio plans to use the additional capital to expand its research and development capabilities, GMP manufacturing lines and high-containment facilities.

Moderna expects to make mFlusiva available in the U.S. ahead of the 2026-2027 respiratory virus season.

Novo Nordisk will also use H1’s technology to support several aspects of clinical research, including trial design, patient enrollment and clinical trial site selection.

The company’s scientific capabilities include chimeric antigen receptor T-cell (CAR-T) therapies and treatments derived from induced pluripotent stem cells (iPSCs).

The companies will work together to generate pharmacological and bioanalytical data needed to advance NB4168 toward clinical development.

The decision follows the failure of the phase 3 Lagoon trial, which did not meet its primary endpoint of overall survival.

AbCellera will oversee discovery and early-stage development activities, while Vertex will finance all research and development costs.

Under the agreement, MiRecule will combine its NAVIgGator platform, which is designed to support the development of precision RNA medicines, with RBBL’s expertise in peptide discovery, development, and manufacturing.